Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
Home - The Pharma Times | Pharma & Health Care News Portal
Saturday, April 27, 2024

The Role of Immunotherapy in Lung Cancer Treatment

Dr Sanchayan Mandal, Consultant - Medical Oncology, HCG EKO Cancer Center Lung cancer remains to be one of the most formidable challenges in oncology. Early-stage...

Biotechnology

MGM Healthcare’s Heart and Lung Transplant Team Performs an ABO-Incompatible Paediatric Heart Transplant on...

CHENNAI, August 23 , 2023 : MGM Healthcare is proud to announce the successful completion of an ABO-incompatible Paediatric Heart Transplant, crossing the blood...

The Future is Here: MASSH Hospital Ushers in a New Era of Smart Healthcare

NEW DELHI , August 29, 2023:  A ground-breaking chapter in the realm of healthcare has unfolded with the official launch of Minimal Access Smart...

IT & Software Support

Appointments

Awards

Financial Results

Approvals

Lupin and Mylan Receive European Marketing Authorization for Nepexto®, Biosimilar Etanercept

Mumbai, June 04, 2020: Lupin Limited (Lupin) and Mylan N.V. (NASDAQ: MYL) today announced that the European Commission (EC) has granted marketing authorization for...

Clinical Trails

Phase III DECISION Trial of Nexavar® (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival...

Berlin, January 3, 2013 – Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase III trial of Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement in progression-free survival. The study, called DECISION, evaluated the efficacy and safety of Nexavar compared to placebo. The safety and tolerability were generally consistent with the known profile of Nexavar. Detailed efficacy and safety analysis from this study are expected to be presented at an upcoming medical meeting. Effective treatment options are urgently needed for patients with RAI-refractory differentiated thyroid cancer,” said Dimitris Voliotis, MD, Vice President, Global Clinical Development Oncology, Bayer HealthCare. “We are pleased that the results of this study demonstrate that Nexavar may provide a treatment option for these patients.

Bulk Drug

Health Care

Alternative Medicine

Eye Care

Protecting Your Eyes: Understanding Conjunctivitis and Preventive Measures During Seasonal Outbreak

By Dr. Shibu Varkey MS, DO, DNB, FRCS(UK) Regional Medical Director, Maxivision Superspeciality Eye Hospital, Tiruchirapalli Conjunctivitis or pink eye is a seasonal infection affecting...

Dr. Agarwals Eye Hospitals opens high-end eyecare facility in Chembur, its 10th in Mumbai

Mumbai, October 05, 2023:  Dr. Agarwals Eye Hospitals has opened a state-of-the-art eyecare hospital in Chembur, Mumbai, at Signature Business Park. The facility, spread...

Winter care tips for Dry eyes

By Dr.Prardhana Reddy – Consultant ophthalmologist & Glaucoma Specialist MaxiVision Super Specialty Eye hospitals group Hyderabad New Delhi, January 08, 2020: The mercury is falling...

Product News

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2019 Congress

Tokyo, September 29, 2019: Eisai Co., Ltd. announced today that a series of abstracts will be presented during the European Society for Medical Oncology...

Media Partners

Spotlight

Investments

Packaging

Latest News

Toyota Group Engaged in Full Production of Medical Face Shields

Toyota expands monthly production capacity to 40,000 units Japan, April 28, 2020 : (JCN Newswire) - Toyota Motor Corporation (Toyota) and Toyota Group companies are...

Brinton Pharmaceuticals receives Series B funding from India Alternatives

Pune, June 18, 2019: India Alternatives Investment Advisors Ltd. invested up to USD 8 million for a significant minority stake in Brinton Pharmaceuticals Limited....

Dental Care

Tips to maintain oral health!

By Dr.MS Prasad, Dental Surgeon, Columbia Asia Referral Hospital Yeshwanthpur It has been said that a person’s real happiness begins from the plate and is...

Hospital Management

Drug Discovery & Development

The Illustrated Guide to Living with Diabetes in India, a Self-management Guide for Diabetics...

Mumbai, Maharashtra, India, Monday, April 22, 2013 -- (Business Wire India) -- 'The Illustrated Guide to Living with Diabetes in India', a practical guide to self-manage diabetes was launched at Kochi on Friday, April 19, 2013 by Sir Michael Hirst, President, International Diabetes Federation (IDF) during the 5 th World Congress of DiabetesIndia. Dr. Shaukat Sadikot, President - Elect, IDF and Prof. Dr. Jean Claude Mbanya, Past-President, IDF was also present during this occasion. The book authored by The Living with Diabetes in India (LWDI), an online community for people with diabetes with over half a million members - and co-published in India by Popular Prakashan, is now available at leading book stores across India and through online retailers.

Suppliers

Technology

Companies

Marketing

Our Partners

Machinery & Equipments